000			a
999			_c20617 _d20617
003			OSt
005			20240118153513.0
008			240118b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_922819 _aDarnifayanti, Darnifayanti
245			_aGenetic polymorphisms associated with sepsis incidence, severity, and outcomes among neonates: A mini‑review
250			_aVol.14(4), Oct-Dec
260			_aMumbai _bWolter Kluwer _c2023
300			_a289-293p.
520			_aGenetic variation remains a topic of great interest due to its potential as a risk factor for various diseases. Interactions between genes contribute to diverse phenotypes in response to factors such as infection. The impact of genetic background on susceptibility and clinical outcomes, particularly in neonatal sepsis, has gained recognition. The variability in sepsis susceptibility and outcomes can be attributed to the genetic diversity in coding regions and regulatory elements of genes related to innate immune response. Recent advances in genomics and technology have shed light on genetic polymorphisms among humans, often represented by single‑nucleotide polymorphisms (SNPs). These SNPs encode proteins crucial for recognizing and responding to pathogenic bacteria, including Toll‑like receptor 4, CD14, tumor necrosis factor‑alpha, as well as interleukin‑1‑10. This literature review specifically discusses the involvement of genetic polymorphism during the pathogenesis stage of sepsis, with an emphasis on previous research findings in neonatal sepsis cases, aiming to discuss the implications of polymorphism in sepsis susceptibility and outcomes.
650		0	_94639 _aPHARMACEUTICS
700			_922820 _aAkmal, Muslim
773	0		_x2231-4040 _tJournal of advanced pharmaceutical technology and research
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10723165/pdf/JAPTR-14-289.pdf _yClick here
942			_2ddc _cAR